Ad Header



The Pulse of the Pharmaceutical Industry

Express Scripts says controlling cancer-drug costs a tough new focus

Written by: | | Dated: Wednesday, April 29th, 2015

(Reuters) – Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new “focus area” will be subduing costs of a growing wave of pricey biotech cancer drugs.

“This is going to be a much slower and much bigger effort over time than what you saw for hepatitis,” Steve Miller, chief medical officer of Express Scripts, told analysts during a conference call. “Cancer is different than any other disease, much more emotional.”



(Reporting by Ransdell Pierson; Editing by Chris Reese)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom